Evidence map›Paper›PMID 41136629›Full record

ArticleNature medicine2025

How HIV research drives health innovation in multiple diseases.

Lawrence Corey, Jirair Ratevosian, Chris Beyrer, Judith Currier, Joseph Eron, Myron S Cohen, Steven G Deeks

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The HIV/AIDS response as we knew it is over: Where do we go from here?Journal of the International AIDS Society · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lawrence CoreyVaccine and Infectious Disease Division, Fred Hutch Cancer Center, Seattle, WA, USA. lcorey@fredhutch.org.
Jirair RatevosianDuke Global Health Institute, Duke University, Durham, NC, USA.
Chris BeyrerDuke Global Health Institute, Duke University, Durham, NC, USA.
Judith CurrierUniversity of California at Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0003-4279-4737
Joseph EronUniversity of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-4938-0644
Myron S CohenUniversity of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Steven G DeeksUniversity of California at San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-6371-747X

Funding

LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6M
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
LOC: HIV Prevention Trials NetworkUM1AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI Sinead Delany-Moretlwe, RAPHAEL J LANDOVITZ · 2011 to 2026
$779.5M
NIAID NIH HHS UM1 AI068614U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) UM1AI068619U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) UM1AI068636
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41136629
PMCPMC13441067

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.